1 January 2025 in Medicinska istrazivanja
Introduction: Capillaroscopy is a non-invasive diagnostic tool used to detect morphological abnormalities in the microcirculation. The assessment of capillaroscopic findings in healthy subjects is likely the area where controversies are most difficult to resolve. This review focuses on capillary architecture in healthy individuals across different age groups. Methods: A search was conducted in PubMed, MEDLINE, and Scopus using the following terms: capillaroscopy, healthy subjects, Raynaud's phenomenon, microcirculation, and microvascular abnormalities. A total of 10 relevant articles were identified. Results: The shape of capillaries and the architecture of the nailfold microvascular network can vary significantly among healthy individuals. The most commonly observed abnormalities in this population include tortuosity, crossovers, homogeneously enlarged loops, neoangiogenic capillaries, and microbleeding. Less frequently, more unusual patterns, such as ramified, bushy, or glomerular loops may be observed. These atypical features require careful evaluation to avoid missing a potential underlying disease. Conclusion: This review critically examines capillaroscopy findings in healthy individuals, taking into account typical nail care practices and age-related changes. These insights may assist clinicians in distinguishing physiological variations from early signs of microvascular damage.
2 January 2026 in Clinical Case Reports
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation and joint destruction, whereas polycythemia vera (PV) is a myeloproliferative neoplasm driven by the Janus kinase (JAK)2 V617F mutation, resulting in erythrocytosis and increased thromboembolic risk. Although JAK inhibitors are established in rheumatology, most selectively inhibit JAK1 and JAK3, sparing JAK2 activity, which is central to PV pathogenesis. We describe a 61‐year‐old woman with seropositive RA and JAK2 V617F‐positive PV. Treatment for polycythemia vera included hydroxyurea. Methotrexate and sulfasalazine were prescribed for rheumatoid arthritis but were withdrawn due to intolerance, and therapy was switched to tofacitinib 5 mg twice daily. Within 3 months, she achieved clinical and ultrasonographic remission of RA, with improvement of inflammatory markers. Hematologic parameters remained stable throughout follow‐up. After 6 months, a mild improvement allowed reduction in hydroxyurea dosing, although further tapering resulted in recurrence of erythrocytosis. After 12 months of therapy, RA remission persisted without adverse events or cytopenias. Tofacitinib demonstrated rheumatologic efficacy but minimal effect on PV‐related hematologic activity.